健康受试者静脉注射 ZMA001 的研究
一项随机、双盲、安慰剂对照、单次剂量递增研究,旨在评估健康受试者静脉注射 ZMA001 的安全性、耐受性和药代动力学
Background:
A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick with PAH, researchers want to find out how the drug affects healthy people.
Objective:
To test a drug (ZMA001) in healthy volunteers.
Eligibility:
Healthy adults aged 18 to 60 years.
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have a urine test for drug use. They will have a test of their heart function.
Participants will come to the clinic for 1 inpatient visit of up to 48 hours.
ZMA001 is a liquid administered through a tube attached to a needle inserted into a vein in the arm. Participants will receive this drug only once, during their inpatient stay. Some participants will receive the drug; others will receive a placebo in Cohort 1 only. A placebo is a treatment that looks just like the real drug but contains no medicine. Participants will not know which treatment they are getting in Cohort 1. Cohorts 2-4 will receive a single dose of the study drug, administered through a tube attached to a needle inserted into a vein in the arm.
After a screening visit, participants will have 1 inpatient visit and up to 8 outpatient visits over 16 weeks after receiving the treatment. Blood draws and other tests will be repeated. Each outpatient visit is approximately 2 hours long.
This study is the first time ZMA001 will be administered to people.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
Study Description:
ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH). The current first-in-human, single ascending-dose study will determine the safety, tolerability, and pharmacokinetics of intravenous ZMA001 in healthy subjects.
Objectives:
Primary Objective: Safety and tolerability of ZMA001 in healthy subjects
Secondary Objectives: Determine the pharmacokinetics of ZMA001 in healthy subjects following a single, intravenous dose
Endpoints:
Primary Endpoint: The number of all-cause, treatment-emergent adverse events, grade 1 and above (following CTCAE v5.0 criteria) through day 113
Secondary Endpoints: For each ZMA001 dose level (1.5, 0.25, 0.50, and 1.0 mg/kg), the following will be determined [Timeframe: Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113]:
- Time to peak drug concentration (Tmax)
- Peak drug concentration (Cmax)
- Area under the drug concentration-time curve (AUC)
- Elimination half-life
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 阶段1
联系人和位置
学习地点
-
-
Maryland
-
Bethesda、Maryland、美国、20892
- National Institutes of Health Clinical Center
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
-
Stated willingness to comply with all study procedures and availability for the duration of the study
-
Male* or female, aged 18 to 60 years, inclusive
-
In good general health as evidenced by medical history
-
Females of childbearing potential agree to use an accepted method of contraception (see below) throughout study participation and for 120 days after study drug infusion.
-
Males sexually active with a female partner must agree to use a condom with spermicide for 120 days after study drug infusion or be surgically sterile for at least 90 days before screening. Males must also agree to not donate sperm for 120 days after study drug administration.
-
Agreement to adhere to Lifestyle Considerations throughout study duration
-
Ability of subject to understand and the willingness to sign a written informed consent document.
- Enrollment of healthy male subjects will be limited to no more than 14 out of the total study cohort of 32 in order to ensure an adequate representation of female subjects.
Accepted methods of contraception for females of childbearing potential:
- Use of an implanted or intrauterine hormonal device for at least 30 consecutive days before study drug infusion
- Use of oral, patch or injectable contraceptives or a vaginal hormonal device for at least 30 consecutive days before study drug infusion
- Use of a non-hormonal intrauterine device for at least 30 consecutive days before study drug infusion
- Two barrier methods such as a diaphragm with spermicide or a condom with spermicide
EXCLUSION CRITERIA:
An individual who meets any of the following criteria prior to informed consent will be excluded from participation in this study:
- Pregnancy or lactation. Females of childbearing potential must have a negative serum Beta-human chorionic gonadotropin test no more than 48 hours from study drug infusion.
- A history of human immunodeficiency virus (HIV) infection.
- History of severe drug or excipient allergy or hypersensitivity
- Known allergy to any of the components of the investigational drug or placebo
- Recent infection or febrile illness within the past 14 days
- Treatment with another investigational drug within the past 30 days or 5 half-lives, whichever is longer
- Any vaccination within the past 4 weeks or receipt of a live-attenuated vaccine within the past 6 months
- Use of tobacco products within the past 3 months
- Illicit drug use (e.g. cocaine, opioids, methamphetamine, PCP) within the past 6 months or positive urine drug screen at Screening Visit
- Marijuana (cannabis) use within the past 30 days or positive urine drug screen at Screening Visit
- History of alcohol abuse within the past 2 years
- Current clinically significant medical illness that is uncontrolled despite appropriate medical treatment including (but not limited to) hematologic, oncologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, infectious, hepatic, dermatologic, psychiatric, neurologic, autoimmune or allergic disease
- Body mass index less than 17 or greater than 32 kg/m^2
- Clinically significant abnormal results on clinical blood testing completed at the Screening Visit
- Electrocardiographic evidence of clinically relevant heart disease
- Diabetes mellitus requiring medical treatment
- Received another monoclonal antibody in the past 30 days
- Use of herbal supplements, or similar products within the past 2 weeks
- Blood donation equal to or above 500 mL within 2 months prior to dosing.
- Any other finding that, in the judgment of the Investigator, would increase the risk of having an adverse outcome from participating in the study.
Justification to exclude minors: Given that the vast majority of patients with PAH are >18 years of age and the fact that this is a first in human study, the risks of including children/minors (ie. subjects < 18 yrs of age) are not justified given the limited potential benefits of including these subjects.
Justification to exclude adults >60 years old: Subjects > 60 years of age are more likely to have comorbid medical conditions that could place them at increased risk of participation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
安慰剂比较:Placebo Cohort 1 (1.5 mg/kg/dose) only
Placebo for ZMA001 is supplied in a single-use 10 mL glass vial. Each vial contains 30 mg/mL of sucrose.Placebo drug is manufactured using the same ingredients as active drug (20 mM histidine-HCl buffer [pH 5.6], 30 mg/mL sucrose, 0.070 w/v% polysorbate 80) excluding ZMA001 antibody and is packed in the same vial. |
30mg/ml Sucrose |
|
实验性的:ZMA001 (BC-NKA-20008)
ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH). |
ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH). |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and tolerability of ZMA001 in healthy subjects
大体时间:day 113
|
The number of all-cause, treatment-emergent adverse events, grade 1 and above (following CTCAE v5.0 criteria) through day 113 |
day 113
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Determine the pharmacokinetics of ZMA001 in healthy subjects following a single, intravenous dose.
大体时间:Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
For each ZMA001 dose level (1.5, 0.25, 0.50, and 1.0 mg/kg), the following will be determined.3. Area under the drug concentration-time curve(AUC) |
Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
|
Determine the pharmacokinetics of ZMA001 in healthy subjects following a single, intravenous dose.
大体时间:Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
For each ZMA001 dose level (1.5, 0.25, 0.50, and 1.0 mg/kg), the following will be determined.2. Peak drug concentration (Cmax) |
Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
|
Determine the pharmacokinetics of ZMA001 in healthy subjects following a single, intravenous dose.
大体时间:Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
For each ZMA001 dose level (1.5, 0.25, 0.50, and 1.0 mg/kg), the following will be determined.1. Time to peak drug concentration (Tmax) |
Pre-infusion, end of infusion, 2, 4, 8, 12, 24, and 48h; Days 8, 15, 22, 29, 57, 85 and 113
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Jason M Elinoff, M.D.、National Heart, Lung, and Blood Institute (NHLBI)
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
其他研究编号
- 10001522
- 001522-H
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
All IPD that underlie results in a publication.
IPD 共享时间框架
Data will be made available at the time of associated publication and the duration of availability is expected to be indefinite but will ultimately be determined by the NHLBI.@@@@@@
IPD 共享访问标准
Data will be shared through the NHLBI BioData Catalyst, which is a controlled access repository.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.